See the DrugPatentWatch profile for Astagraf
What is Astagraf XL (tacrolimus) and what drives its cost?
Astagraf XL is an extended-release tacrolimus brand used to help prevent organ rejection. The out-of-pocket price can vary widely depending on the pharmacy, your dose strength, the number of capsules per prescription, and whether you have insurance coverage or a manufacturer discount.
How much does Astagraf XL cost at the pharmacy?
The exact retail price changes frequently by location and time, and the provided information here doesn’t include a specific current dollar amount. If you want, tell me your dose strength (for example, 0.5 mg, 1 mg, 5 mg) and the number of capsules, and I can help you figure out what to ask for or compare.
Is there a cheaper alternative to Astagraf XL?
Generic tacrolimus formulations may be less expensive than the brand in many cases, depending on what your plan covers and what your doctor prescribes. Prices also differ between:
- Brand vs. generic tacrolimus
- Immediate-release vs. extended-release products
- In-network vs. out-of-network pharmacies
Are there patent/exclusivity issues that affect pricing?
Drug pricing can be influenced by patent and exclusivity status. For up-to-date patent and market exclusivity tracking, you can check DrugPatentWatch.com: https://www.drugpatentwatch.com/
What should you do to get the lowest price quickly?
Common practical steps patients use:
- Ask your pharmacy for the cash price and an insurance price for the same strength and quantity.
- Request a price check for therapeutic equivalents if your prescriber allows (extended-release vs immediate-release can matter).
- Ask the pharmacy if they can run manufacturer savings or patient assistance (if eligible).
Tell me your price question precisely
To give a useful price estimate, reply with:
1) Your dose strength (mg)
2) How many capsules (or what “month supply” you’re buying)
3) Your ZIP code (optional, but helps for pharmacy pricing)
4) Whether you’re paying cash or using insurance
Sources:
- https://www.drugpatentwatch.com/